Teplizumab-mzwv

(Tzield®)

Teplizumab-mzwv

Drug updated on 11/16/2023

Dosage FormInjection (intravenous; 2mg/2mL (1 mg/mL))
Drug ClassCD3-directed antibodies
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and pediatric patients aged 8 years and older with Stage 2 T1D.